EYPT Q2 2025 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-43.7% YoY

Gross Profit

$5M96.9% margin

Operating Income

-$62M-1166.8% margin

Net Income

-$59M-1114.3% margin

EPS (Diluted)

$-0.85

QoQ Revenue Growth

-78.2%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$64M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$301M

Total Liabilities

$55M

Stockholders' Equity

$246M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$9M	-43.7%
Gross Profit	$5M	$8M	-36.0%
Operating Income	-$62M	-$35M	-80.1%
Net Income	-$59M	-$31M	-92.8%

Revenue Segments

License And Collaboration Agreement

$5M100%